ABSTRACT
BACKGROUND Data from certain subgroups of clinical interest may not be presented in primary manuscripts or conference abstract presentations. In an effort to enable secondary data analyses, we propose a workflow to retrieve unreported subgroup survival data from published Kaplan-Meier (KM) curves.
METHODS We developed KMSubtraction, an R-package that retrieves patients from unreported subgroups by matching participants on KM curves of the overall cohort to participants on KM curves of a known subgroup with follow-up time. By excluding matched patients, the opposing unreported subgroup may be retrieved. Reproducibility and limits of error of the KMSubtraction workflow were assessed by comparing unmatched patients against the original survival data of subgroups from published datasets and simulations. Monte Carlo simulations were utilized to evaluate the effect of the reported subgroup proportion, missing data, censorship proportion in the overall and subgroup cohort, sample size and number-at-risk table intervals on the limits of error of KMSubtraction. 3 matching algorithms were explored – minimal cost bipartite matching, Mahalanobis distance matching, and nearest neighbor matching by logistic regression.
RESULTS The validation exercise found no material systematic error and demonstrates the robustness of KMSubtraction in deriving unreported subgroup survival data. Limits of error were small and negligible on marginal Cox proportional hazard models comparing reconstructed and original survival data of unreported subgroups. Extensive Monte Carlo simulations demonstrate that datasets with high reported subgroup proportion (r=0.467, p<0.001), small dataset size (r=-0.374, p<0.001) and high proportion of missing data in the unreported subgroup (r=0.553, p<0.001) were associated with uncertainty are likely to yield high limits of error with KMSubtraction.
CONCLUSION While KMSubtraction demonstrates robustness in deriving survival data from unreported subgroups, the implementation of KMSubtraction should take into consideration the aforementioned limitations. The limits of error of KMSubtraction, as reflected by the mean |ln(HR)| from converged Monte Carlo simulations may guide the interpretation of reconstructed survival data of unreported subgroups.
Competing Interest Statement
RS has received honoraria from Bristol-Myers Squibb, Lilly, Roche, Taiho, Astra Zeneca, DKSH and MSD; has advisory activity with Bristol-Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD and AstraZeneca; received research funding from MSD and Paxman Coolers; and has received travel grants from AstraZeneca, Eisai, Roche and Taiho Pharmaceutical.
Funding Statement
Not applicable.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
RS is supported by the National Medical Research Council (NMRC) (NMRC/Fellowship/0059/2018 and NMRC/TA/0014/2020). All other authors have no funding to declare.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest: RS has received honoraria from Bristol-Myers Squibb, Lilly, Roche, Taiho, Astra Zeneca, DKSH and MSD; has advisory activity with Bristol-Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD and AstraZeneca; received research funding from MSD and Paxman Coolers; and has received travel grants from AstraZeneca, Eisai, Roche and Taiho Pharmaceutical.
Financial disclosures: RS is supported by the National Medical Research Council (NMRC) (NMRC/Fellowship/0059/2018 and NMRC/TA/0014/2020). All other authors have no funding to declare.
Data Availability
Not applicable, the data was derived from simulations.
